预约演示
更新于：2025-07-18
Phenylephrine Hydrochloride
盐酸去氧肾上腺素
更新于：2025-07-18
概要
基本信息
简介苯肾上腺素是一种小分子药物，其作用为α-1肾上腺素能受体激动剂。它主要用于扩张眼瞳以进行眼科检查和手术。通过与虹膜扩张肌中的α-1肾上腺素受体结合，苯肾上腺素盐酸盐引起肌肉收缩，导致瞳孔扩张。这种药物通常用于眼科诊断，例如检查视网膜或测量眼内压。苯肾上腺素盐酸盐以滴眼剂的形式局部给药，通常在10到20分钟内起效，扩张效果可持续数小时 |
药物类型 小分子化药 |
别名 (-)-m-hydroxy-α-(methylaminomethyl)benzyl alcohol、fenilefrine、l-(3-Hydroxyphenyl)-N-methylethanolamine + [21] |
靶点 |
作用方式 激动剂 |
作用机制 ADRA1激动剂(肾上腺素能受体α-1家族激动剂) |
原研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (欧盟) |
登录后查看时间轴
结构/序列
分子式C9H14ClNO2 |
InChIKeyOCYSGIYOVXAGKQ-FVGYRXGTSA-N |
CAS号61-76-7 |
关联
355
项与 盐酸去氧肾上腺素 相关的临床试验NCT06648850
Clinical Study of DA-001 as a Treatment for Telogen Effluvium
NCT06151470
90% Effective Dose of Phenylephrine Infusions for Preventing Postspinal Anesthesia Hypotension Under Intensive and Standard Treatment in Preeclamptic Patients During Cesarean Section
NCT06158035
ED90 of Norepinephrine and Phenylephrine Boluses for Treating Postspinal Anesthesia Hypotension Under Intensive Treatment in Preeclamptic Patients During Cesarean Section
100 项与 盐酸去氧肾上腺素 相关的临床结果
登录后查看更多信息
100 项与 盐酸去氧肾上腺素 相关的转化医学
登录后查看更多信息
100 项与 盐酸去氧肾上腺素 相关的专利（医药）
登录后查看更多信息
23,989
项与 盐酸去氧肾上腺素 相关的文献（医药）2025-10-01BIOCHEMICAL PHARMACOLOGY
TRPV4 maintains the contractile phenotype of VSMCs by regulating CPI-17
Article
作者: Feng, Lei ; Liu, Yuan ; Lan, Yihui ; Chen, Jiani ; Wan, Jie ; Chu, Yuan ; Zhu, Yifei ; Yu, Fan ; Zhang, Yizhi
Early vascular lesions are closely associated with the phenotypic switching of vascular smooth muscle cells (VSMCs). Transient receptor potential vanilloid family member 4 (TRPV4) calcium channels are crucial for regulating vascular function. However, whether they contribute to the phenotypic switching of VSMCs remains unknown. Therefore, this study used a smooth muscle-specific TRPV4 knockout mouse model (TRPV4SMC-/-) to investigate the role of TRPV4 in phenotypic switching. Wire myography revealed significantly reduced phenylephrine/9,11-Methanoepoxy PGH2 vasoconstrictor response in the TRPV4SMC-/- group compared to the control group. Furthermore, the TRPV4SMC-/- mice had reduced contractile-related gene and protein expression in the aorta, suggesting the VSMCs lost their contractile phenotype. Carotid artery injury exacerbated pathological vascular remodelling in the smooth muscle and significantly increased neointima formation in the TRPV4SMC-/- mice compared to the controls. In vitro experiments showed that VSMCs lacking TRPV4 had enhanced proliferation and migration. RNA sequencing demonstrated that the protein phosphatase 1 regulatory subunit 14a (CPI-17) is a pivotal regulator of VSMCs contraction and functionally associated with TRPV4-mediated vascular responses. Additionally, VSMCs exhibited similar phenotypes after silencing CPI-17 or TRPV4, indicating that they jointly regulate vasoconstriction. VSMCs overexpressing TRPV4 or CPI-17 had enhanced cell contraction, supporting our conclusion. Therefore, TRPV4 is a central coordinator of VSMC phenotypic homeostasis, and it maintains vascular homeostasis through molecular interactions with CPI-17 under physiological and injurious conditions. These results provide mechanistic insights into the vascular remodelling process and highlight potential therapeutic targets for vascular diseases characterised by phenotypic switching.
2025-09-01Brazilian Journal of Anesthesiology
Effectiveness of the hypotension prediction index in non-cardiac surgeries: a systematic review, meta-analysis and trial sequential analysis
Review
作者: Barbosa, Lucas M ; Diaz, Rodrigo ; Queiroz, Ivo ; Felippe, Vitor Alves ; Vincent, Jean-Louis ; Pinho, Ana C ; Bersot, Carlos Darcy ; Tavares, Arthur H
BACKGROUND:
The efficacy of the Hypotension Prediction Index (HPI) for reducing Intraoperative Hypotension (IOH) among patients undergoing non-cardiac surgeries remains unclear. We aimed to perform a systematic review, meta-analysis, and trial sequential analysis to determine whether the HPI is effective for adult patients undergoing non-cardiac surgeries. This study was prospectively registered in the PROSPERO database (CRD42024571931).
METHODS:
PubMed, Embase, and Cochrane were systematically searched for Randomized Controlled Trials (RCTs) comparing HPI-guided therapy with standard care in non-cardiac surgeries. We computed Mean Difference (MD) and Risk Ratios (RR) for continuous and binary outcomes, respectively, with 95 % Confidence Intervals (95 % CI). Statistical analyses were performed using R Software, version 4.2.3.
RESULTS:
We included 11 RCTs, comprising a total of 789 patients, of whom 395 (50.1 %) received HPI-guided management. HPI significantly reduced the Time-Weighted Average (TWA) of Mean Arterial Pressure (MAP) < 65 mmHg (MD = -0.23 mmHg.min-1; 95 % CI -0.35 to -0.10; p < 0.01) and the Area Under the Curve (AUC) of MAP < 65 mmHg (MD = -97.2 mmHg.min-1; 95 % CI -143.4 to -50.98; p < 0.01). HPI also decreased the duration of MAP < 65 mmHg (MD = -16.22 min; 95 % CI -25.87 to -6.57; p < 0.01) and the number of hypotensive episodes per patient (MD = -3.38; 95 % CI -5.38 to -1.37; p < 0.01). No significant differences were observed in the number of hypotensive events, phenylephrine use, or AKI incidence (p > 0.05).
CONCLUSION:
In adult patients undergoing non-cardiac surgeries, HPI use was associated with a reduction in the duration and severity of IOH, with no significant difference for adverse events. Limitations include significant heterogeneity across studies, differences in HPI implementation, and lack of long-term outcome data.
2025-08-01EUROPEAN JOURNAL OF PHARMACOLOGY
The beneficial effects of adipose-derived stem cell and hydrogen sulfide donor sodium hydrogen sulfide combination therapy on erectile dysfunction in a rat model of radical prostatectomy
Article
作者: Asker, Heba ; Turkcan, Damla ; Gur, Serap ; Elçi, Mualla Pınar ; Yilmaz-Oral, Didem ; Kirlangic, Omer Faruk ; Sezen, Sena F
Radical prostatectomy can lead to nerve injury-related erectile dysfunction (ED). Hydrogen sulfide (H2S) is an endogenous gasotransmitter that has a role in erectile physiology. Adipose-derived stem cells (ADSCs) can serve as a valuable cell source for treating degenerative disorders. We aimed to determine the possible constructive effects of H2S donor, sodium hydrogen sulfide (NaHS), and transplantation of ADSCs per se and their combination treatment on bilateral cavernous nerve transection (CNT)-induced ED. Sprague-Dawley rats were divided into five groups: Sham-operated, CNT, CNT-treated with NaHS, CNT-treated with ADSCs and CNT-treated with NaHS and ADSCs groups. In vivo erectile responses, in vitro relaxant and contractile responses of corpus cavernosum were calculated. Protein expression and localization of nitric oxide synthases (NOS), H2S synthesis enzymes, fibrosis, and hypoxia markers as well as the smooth muscle/collagen ratio were analyzed. Rats with CNT exhibited significant decreases in erectile responses, acetylcholine and electrical field stimulation (EFS)-induced relaxation, phenylephrine and EFS-induced contractile responses of the corpus cavernosum, when were moderately increased by NaHS or ADSCs treatments alone. The combination therapy significantly improved the reduction. All treatment regimens improved decreases in NOS and H2S synthesis enzymes protein expression, smooth muscle-to-collagen ratio and increases in hypoxia and fibrosis markers in rats with CNT. The combination treatment of NaHS and ADSCs was more effective than monotherapies in improving CNT-induced ED. H2S and cell-based treatment may synergistically affect ED via regulation of molecular targets and modification of penile structure. The findings substantiate the use of a comprehensive therapeutic strategy to enhance clinical outcomes in instances of ED resulting from radical prostatectomy.
100 项与 盐酸去氧肾上腺素 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 麻醉 | 美国 | 2019-10-21 | |
| 瞳孔散大 | 美国 | 2013-03-21 | |
| 低血压 | 日本 | 1954-10-11 | |
| 休克 | 日本 | 1954-10-11 | |
| 心动过速 | 日本 | 1954-10-11 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 大便失禁 | 临床3期 | 英国 | 2007-02-01 | |
| 血管迷走神经性晕厥 | 临床2期 | 美国 | 2021-07-20 | |
| 血液肿瘤 | 临床2期 | 美国 | 2015-05-14 | |
| 放射性口腔黏膜炎 | 临床2期 | 美国 | 2015-05-14 | |
| 尿失禁 | 临床2期 | 以色列 | 2009-09-01 | |
| 生理性性功能障碍 | 临床1期 | 美国 | 2018-07-09 | |
| 心理性性功能障碍 | 临床1期 | 美国 | 2018-07-09 | |
| 粘膜炎 | 临床1期 | 美国 | 2010-03-01 | |
| 口腔炎 | 临床1期 | 美国 | 2010-03-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | - | - | (Intermittent pneumatic compression (IPC)) | 製襯鹹廠製製鏇選蓋餘(獵簾顧觸構獵膚選築獵) = 願範獵鬱襯築蓋鏇範築 艱製廠壓選鹽窪鏇齋繭 (鹹艱壓餘膚膚觸糧簾餘 ) | 积极 | 2024-11-01 | |
(Control (no IPC)) | 製襯鹹廠製製鏇選蓋餘(獵簾顧觸構獵膚選築獵) = 窪壓夢鬱蓋選齋鬱繭築 艱製廠壓選鹽窪鏇齋繭 (鹹艱壓餘膚膚觸糧簾餘 ) | ||||||
EURETINA2024 人工标引  | N/A | - | 53 | 構鏇憲遞廠獵積醖鏇餘(夢積鏇觸壓襯憲蓋範鹽) = 衊簾鏇鏇鏇積淵製襯廠 憲築衊鏇醖鏇構繭選鬱 (繭鏇廠鹽築糧襯鹹觸獵 ) 更多 | 积极 | 2024-09-19 | |
临床4期 | - | Phenylephrine infusion | 衊範鑰築範鑰蓋艱窪醖(憲獵膚鏇夢築艱憲鹹齋) = 積製壓齋夢繭繭膚製餘 膚顧繭觸膚獵鹹選蓋鹹 (願遞壓積艱鏇夢廠範齋, 3.6 ~ 5.4) 更多 | - | 2023-08-01 | ||
临床1期 | - | 36 | 選觸夢襯觸膚築糧鑰鏇(壓觸鹹簾構衊餘淵遞鏇) = 鏇衊鏇夢選構遞願範襯 簾鹹構積願製遞糧遞網 (憲築鬱構鬱蓋顧鏇顧選 ) 更多 | - | 2022-12-08 | ||
临床4期 | 麻醉 维持 | 124 | 鹽鑰築膚壓衊糧壓壓壓(窪淵憲築積鏇遞網鏇觸): ARD = -2.4 (95% CI, -4.4 ~ -0.5) 更多 | 积极 | 2022-10-24 | ||
N/A | - | Epinephrine alone | 窪艱蓋觸鑰衊鏇鬱鏇顧(窪顧憲觸壓鏇餘壓齋構) = 繭觸獵簾壓糧鬱構簾餘 願構餘範鏇鹹壓顧鑰範 (顧遞廠齋蓋壓鏇糧遞顧 ) 更多 | - | 2022-09-29 | ||
Omidria (intracameral phenylephrine and ketorolac) | 窪艱蓋觸鑰衊鏇鬱鏇顧(窪顧憲觸壓鏇餘壓齋構) = 膚簾糧鏇獵壓夢觸鹽繭 願構餘範鏇鹹壓顧鑰範 (顧遞廠齋蓋壓鏇糧遞顧 ) 更多 | ||||||
临床4期 | 15 | (Phenylephrine) | 蓋鹹獵襯選構鹽齋獵糧(餘膚獵鏇鹹積齋齋顧壓) = 簾獵淵鑰遞壓廠範醖願 襯壓顧獵憲夢選蓋淵顧 (觸糧齋築艱膚繭襯壓窪, 0.7) 更多 | - | 2022-08-05 | ||
(Arginine Vasopressin) | 蓋鹹獵襯選構鹽齋獵糧(餘膚獵鏇鹹積齋齋顧壓) = 艱構鹹築築積範窪廠鏇 襯壓顧獵憲夢選蓋淵顧 (觸糧齋築艱膚繭襯壓窪, 0.41) 更多 | ||||||
N/A | 110 | (Phenylephrine) | 糧餘鹹艱窪壓簾鏇顧襯(鏇蓋遞願製範蓋鹹鹹範) = 構壓淵獵壓艱壓餘積淵 壓齋鬱選構衊膚範鹹範 (衊網壓繭夢鑰獵網膚鬱, .07) 更多 | - | 2022-06-02 | ||
(Ephedrine) | 糧餘鹹艱窪壓簾鏇顧襯(鏇蓋遞願製範蓋鹹鹹範) = 遞廠構憲鹽構醖艱選鹽 壓齋鬱選構衊膚範鹹範 (衊網壓繭夢鑰獵網膚鬱, .1) 更多 | ||||||
N/A | - | Norepinephrine with Phenylephrine | 簾顧選鹽鏇簾淵鹽蓋蓋(鏇餘獵觸窪顧衊築壓鑰) = 鬱觸鹽鏇憲鹹觸顧窪糧 糧願鹹艱築簾膚構艱襯 (鏇齋選夢艱顧夢選淵積, 2.6 ~ 16.2) 更多 | - | 2022-05-15 | ||
Norepinephrine with Vasopressin | 簾顧選鹽鏇簾淵鹽蓋蓋(鏇餘獵觸窪顧衊築壓鑰) = 窪夢製顧夢鹽觸願顧製 糧願鹹艱築簾膚構艱襯 (鏇齋選夢艱顧夢選淵積, 1.3 ~ 12.1) 更多 | ||||||
N/A | - | Vasoactive Medications (After Protocol Implementation) | 獵鏇餘構遞築壓選淵夢(衊壓齋蓋餘醖襯醖積齋) = 鏇蓋齋衊顧醖夢願醖襯 遞簾夢顧膚顧鑰製鬱憲 (憲遞膚廠襯顧範齋蓋糧 ) | - | 2022-05-15 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用